Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Ginkgo_Bioworks
gptkb:Glaxo_Smith_Kline gptkb:Twitter_account |
| gptkbp:application |
agriculture
therapeutics industrial biotechnology |
| gptkbp:awards |
various industry recognitions
|
| gptkbp:ceo |
Erik Holmlin
|
| gptkbp:collaborations |
pharmaceutical companies
research institutions biopharmaceutical companies |
| gptkbp:community |
gptkb:Research_Institute
biotech industry |
| gptkbp:community_involvement |
public engagement
educational initiatives |
| gptkbp:competitors |
gptkb:Editas_Medicine
gptkb:Intellia_Therapeutics gptkb:CRISPR_Therapeutics |
| gptkbp:employees |
over 100
|
| gptkbp:focus |
gene editing
|
| gptkbp:founded |
gptkb:2014
|
| gptkbp:founder |
gptkb:Jason_Kelly
|
| gptkbp:future_plans |
global reach
new product development expansion plans increased partnerships innovation in CRISPR technology |
| gptkbp:headquarters |
gptkb:Menlo_Park,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Synthego
|
| gptkbp:impact |
gptkb:Research_Institute
medical advancements agricultural improvements biotechnology innovations |
| gptkbp:industry |
genomics
|
| gptkbp:invention |
multiple CRISPR-related patents
|
| gptkbp:investment |
various venture capital firms
|
| gptkbp:market |
global genomics market
|
| gptkbp:mission |
accelerate research and development in genomics.
|
| gptkbp:partnerships |
various academic institutions
|
| gptkbp:platform |
automated CRISPR design
|
| gptkbp:products |
CRISPR kits
|
| gptkbp:receives_funding_from |
gptkb:Company
|
| gptkbp:research |
genetic engineering
|
| gptkbp:revenue |
growing annually
|
| gptkbp:services |
genome engineering
|
| gptkbp:sustainability |
environmental responsibility
commitment to ethical practices |
| gptkbp:technology |
gptkb:CRISPR-Cas9
gene editing tools |
| gptkbp:vision |
making gene editing accessible
transforming genetic research |
| gptkbp:website |
www.synthego.com
|